Pharmacogenomic Modulators of Impaired Exercise Adaptation in Statin Users

  • End date
    Jul 1, 2021
  • participants needed
  • sponsor
    University of Kansas Medical Center
Updated on 26 January 2021


HMG-CoA reductase inhibitors (statins) have beneficial effects (prevent stroke, heart attack) but also some bad ones (block some good effects of exercise). Individuals have genetic variations in proteins that metabolize/transport statins. We hypothesize that these variations modulate the relationship between statin use and lack of benefit from exercise. We will test this by having statin-users do supervised exercise for 6 weeks, measuring the cardiorespiratory fitness before/after and correlating this to genetic variations present in the patient.

Condition HMG-CoA Reductase Inhibitor Toxicity, HMG-CoA Reductase Inhibitor Toxicity, HMG-CoA Reductase Inhibitor Toxicity
Treatment Exercise
Clinical Study IdentifierNCT04636138
SponsorUniversity of Kansas Medical Center
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age between 35 yrs and 65 yrs?
Gender: Male or Female
Do you have any of these conditions: Do you have HMG-CoA Reductase Inhibitor Toxicity??
We will study English-speaking adults (aged 35-65 years)
who are overweight or obese (body-mass index [BMI] 25-43), currently taking
high-dose atorvastatin (80mg once daily) for primary prevention of
cardiovascular disease and/or stroke, are sedentary (<30 minutes of structured
exercise weekly), willing to participate in supervised exercise three times
weekly and to not make intentional changes to their diet during the study

Exclusion Criteria

We will exclude patients who (a) smoke, (b) are pregnant or breastfeeding, (c)
use other medications that affect lipid metabolism (e.g. fibric acid, fish
oil), (d) who are markedly functional debilitated and unable to exert 4
metabolic equivalents (METs) of energy (e.g. unable to climb a flight of
stairs without stopping), or (e) who have been advised by a physician to avoid
exercise due to comorbid serious cardiovascular disease, (f) uncontrolled
diabetes (A1c > 8), uncontrolled thyroid disease, HIV/AIDS, cancer, (g)
history of myocardial infarction or stroke, or (h) history of statin-induced
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note